NVO: Novo Nordisk A/S - Summary | Jitta

Novo Nordisk A/S

NYSE:NVO

Price
$84.45
Loss Chance
39.3%
7.46JITTA SCORE
171.50%Over Jitta Line
Jitta Ranking
87 / 1,009
1,175 / 4,503
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (59)
Recent Business Performance (62)
Financial Strength (90)
Return to Shareholders (92)
Competitive Advantage (69)
Jitta Signs
Revenue and EarningConsistent
Recent Business PerformanceEarning Growth Last Year
Debt LevelLow Long Term Debt
Return on EquityConsistently High
Dividend PayoutIncreasing Every Year
Share RepurchaseEvery Year
CapExVery Low
Interest Coverage RatioVery Good
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
7.46
171.50%
2.02
152.69%
2.29
> 1,000%
Pharmaceuticals
5.15
1.41%
3.62
7.73%
4.51
43.22%
COMPANY DESCRIPTION
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson’s diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.